Health: Vaccine Aims to Wipe Out Ear, Sinus Infections

[Guest guest]

Butch,

What do you think about this? Will we find out 10 or 20 years from now that

it caused a more serious problem? I am concerned.

Thanks,

Donna

 

 

 

[Guest guest]

Wow Butch, this is just what the world needs, another vaccine!

 

My son who will be eight in November had his first round of vaccines

but will not have anymore and my daughter who will be four in

October has not had a one and will not.

 

Funny thing is last year there was a break out of measles in my

son's school. All the children who got sick had been vaccinated.

 

The great news here is my children are both in the seventeen

percentile. Both my son and daughter never had an ear infection and

they are both past the age of three. Hmm, I wonder if not getting

vaccines had anything to do with that… I must confess though, my

son has been exposed to Essential Oils since six months of age and

Mary has been exposed to Essential Oils from birth.

 

My children eat and drink allot of stuff that is not that good for

them just like the other children in the neighborhood but last year

when all were sick and home for days and some over a week, and some

repeatedly, Johnny was going to school and feeling great.

 

I will take my EOs over the vaccines any day.

 

John

http://ancienthealingoils.com

 

 

, Butch Owen <butchbsi

wrote:

>

> Vaccine Aims to Wipe Out Ear, Sinus Infections

>

> POSTED: 1040 GMT (1840 HKT), September 26, 2006

>

> WASHINGTON (Reuters) -- U.S. researchers said Tuesday that they are

> starting trials of a new vaccine aimed at wiping out childhood ear

and

> sinus infections and many cases of bronchitis in adults.

>

> Unlike virtually all other vaccines on the market, this one will

not be

> aimed at saving lives, but at preventing nuisance illnesses, the

> researchers said.

>

> " We are now in an era where we look to vaccines that make life

better, "

> said Dr. Michael Pichichero, a professor of microbiology,

immunology,

> pediatrics, and medicine at the University of Rochester Medical

Center,

> who is leading the trial.

>

> The vaccine will target Nontypeable Haemophilus influenzae or NTHi,

> which is the main remaining cause of ear and sinus infections and

> bronchitis, now that vaccines exist for various forms of

streptococcal

> bacteria and Haemophilus influenzae B, the previous leading causes.

>

> " For ear infections they are the No. 1 cause, for sinus infections

they

> are the No. 1 cause and for bronchitis in adults they are the No. 1

> cause, but they do not invade the bloodstream and cause life-

threatening

> illness in normal people, " Pichichero said in a telephone

interview.

>

> While ear infections are never fatal, they can cause serious

damage in

> some children, Pichichero noted. He said 83 percent of U.S.

children

> experience one or more ear infections by age 3 and in some cases

hearing

> loss becomes permanent.

>

> And the infections force children to visit clinics and emergency

rooms,

> and are the leading reason for antibiotic prescriptions. Experts

agree

> antibiotics are overused in the United States, which wastes money

and

> also helps " superbug " bacteria evolve that resist the drugs.

>

> A team at Rochester also helped develop the vaccine marketed by

Wyeth as

> Prevnar, used to protect infants and toddlers against some bacteria

> strains that can cause pneumonia, meningitis and ear infections.

>

> GlaxoSmithKline is working on a rival to Prevnar.

>

> The U.S. Centers for Disease Control and Prevention says Prevnar's

use

> has reduced pneumonia rates from the streptococcal strains it

targets by

> 78 percent.

>

> The University of Rochester announced on Tuesday it had won a $3.5

> million grant from the National Institute of Deafness and

Communication

> Disorders, one of the National Institutes of Health, to develop

the new

> vaccine.

>

> " I think the reason that this one has not moved forward at a

faster pace

> despite the discovery of the potential vaccine ingredients ... (is

that)

> up to now virtually all our vaccines have been focused on

> life-threatening illness, " Pichichero said.

>

> The vaccine uses little pieces of the bacteria that cause the

infections

> to stimulate an immune response. As the bacteria are all in the

same

> family, it should protect against a broad range of strains,

Pichichero said.

>

> Testing has begun. " We plan to enroll a total of 400 children and

so far

> have enrolled 20, " he said.

>

> The university also has a $500,000 grant from the Thrasher

Foundation,

> which pays for research into pediatric diseases, to study a new

vaccine

> against Streptococcus pneumoniae strains not included in Prevnar's

> formulation.

>

> " Our ultimate goal would be to combine the three ingredients from

the

> Nontypeable Haemophilus influenzae vaccine with the streptococcal

> vaccine, giving a vaccine that would prevent 90 percent of ear

> infections, sinus infections and bronchitis, " Pichichero said.

>

> That would leave cold viruses as the leading cause of respiratory

> diseases, he said.

>

> Copyright 2006 Reuters. All rights reserved.

>

[Guest guest]

Vaccine Aims to Wipe Out Ear, Sinus Infections

 

POSTED: 1040 GMT (1840 HKT), September 26, 2006

 

WASHINGTON (Reuters) -- U.S. researchers said Tuesday that they are

starting trials of a new vaccine aimed at wiping out childhood ear and

sinus infections and many cases of bronchitis in adults.

 

Unlike virtually all other vaccines on the market, this one will not be

aimed at saving lives, but at preventing nuisance illnesses, the

researchers said.

 

" We are now in an era where we look to vaccines that make life better, "

said Dr. Michael Pichichero, a professor of microbiology, immunology,

pediatrics, and medicine at the University of Rochester Medical Center,

who is leading the trial.

 

The vaccine will target Nontypeable Haemophilus influenzae or NTHi,

which is the main remaining cause of ear and sinus infections and

bronchitis, now that vaccines exist for various forms of streptococcal

bacteria and Haemophilus influenzae B, the previous leading causes.

 

" For ear infections they are the No. 1 cause, for sinus infections they

are the No. 1 cause and for bronchitis in adults they are the No. 1

cause, but they do not invade the bloodstream and cause life-threatening

illness in normal people, " Pichichero said in a telephone interview.

 

While ear infections are never fatal, they can cause serious damage in

some children, Pichichero noted. He said 83 percent of U.S. children

experience one or more ear infections by age 3 and in some cases hearing

loss becomes permanent.

 

And the infections force children to visit clinics and emergency rooms,

and are the leading reason for antibiotic prescriptions. Experts agree

antibiotics are overused in the United States, which wastes money and

also helps " superbug " bacteria evolve that resist the drugs.

 

A team at Rochester also helped develop the vaccine marketed by Wyeth as

Prevnar, used to protect infants and toddlers against some bacteria

strains that can cause pneumonia, meningitis and ear infections.

 

GlaxoSmithKline is working on a rival to Prevnar.

 

The U.S. Centers for Disease Control and Prevention says Prevnar's use

has reduced pneumonia rates from the streptococcal strains it targets by

78 percent.

 

The University of Rochester announced on Tuesday it had won a $3.5

million grant from the National Institute of Deafness and Communication

Disorders, one of the National Institutes of Health, to develop the new

vaccine.

 

" I think the reason that this one has not moved forward at a faster pace

despite the discovery of the potential vaccine ingredients ... (is that)

up to now virtually all our vaccines have been focused on

life-threatening illness, " Pichichero said.

 

The vaccine uses little pieces of the bacteria that cause the infections

to stimulate an immune response. As the bacteria are all in the same

family, it should protect against a broad range of strains, Pichichero said.

 

Testing has begun. " We plan to enroll a total of 400 children and so far

have enrolled 20, " he said.

 

The university also has a $500,000 grant from the Thrasher Foundation,

which pays for research into pediatric diseases, to study a new vaccine

against Streptococcus pneumoniae strains not included in Prevnar's

formulation.

 

" Our ultimate goal would be to combine the three ingredients from the

Nontypeable Haemophilus influenzae vaccine with the streptococcal

vaccine, giving a vaccine that would prevent 90 percent of ear

infections, sinus infections and bronchitis, " Pichichero said.

 

That would leave cold viruses as the leading cause of respiratory

diseases, he said.

 

Copyright 2006 Reuters. All rights reserved.